Zhao Xiumiao, Liu Zhaoxia, Chen Tingtao
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Queen Mary School, Nanchang University, Nanchang 330031, China.
Pharmaceutics. 2023 Mar 15;15(3):948. doi: 10.3390/pharmaceutics15030948.
Ovarian cancer represents one of the most challenging gynecologic cancers which still has numerous unknowns on the underlying pathogenesis. In addition to the verified contributors such as genomic predisposition and medical history in the carcinogenesis, emerging evidence points out the potential role of vaginal microbiota in ovarian cancer. Recent studies have underlined the presence of vaginal microbial dysbiosis in cancer cases. Increasing research also indicates the potential correlations between vaginal microbes and cancer carcinogenesis, progression and treatment. Currently, compared with other gynecologic cancers, reports on the roles of vaginal microbiota in ovarian cancer remain scarce and fragmentary. Therefore, in this review, we summarize the roles of vaginal microbiota in various gynecologic diseases, particularly focusing on the potential mechanisms and possible applications of vaginal microbiota in ovarian cancer, giving insight into the involvement of vaginal microbiota in gynecologic cancer treatment.
卵巢癌是最具挑战性的妇科癌症之一,其潜在发病机制仍有诸多未知之处。除了已证实的致癌因素,如基因组易感性和病史外,新出现的证据指出了阴道微生物群在卵巢癌中的潜在作用。最近的研究强调了癌症病例中存在阴道微生物失调。越来越多的研究还表明阴道微生物与癌症发生、发展和治疗之间存在潜在关联。目前,与其他妇科癌症相比,关于阴道微生物群在卵巢癌中作用的报道仍然稀少且不完整。因此,在本综述中,我们总结了阴道微生物群在各种妇科疾病中的作用,特别关注阴道微生物群在卵巢癌中的潜在机制和可能应用,深入了解阴道微生物群在妇科癌症治疗中的参与情况。